Revenue generation has completely ceased, with the company reporting zero top-line growth for multiple consecutive quarters following the abandonment of its clinical development programs.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 |
|---|
| Sales/Revenue | 0 | 0 | 8K | 3.37M | 1.18M | 1.75M | 545K | 2.22M | 2.52M | 2.44M | 444K | 0 | 0 | 0 |
| Revenue Growth % | - | -100% | -99.76% | 185.68% | -32.73% | 221.83% | -75.49% | -11.75% | 3.11% | 450.45% | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14.9M | 0 | 159K | 54K | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | 591.15% | - | 35.81% | - | - | - |
| Gross Profit | 0 | 0 | 8K | 3.37M | 1.18M | 1.75M | 545K | 2.22M | -12.38M | 2.44M | 285K | -54K | 0 | 0 |
| Gross Margin % | - | - | 100% | 100% | 100% | 100% | 100% | 100% | -491.15% | 100% | 64.19% | - | - | - |
| Gross Profit Growth % | - | -100% | -99.76% | 185.68% | -32.73% | 221.83% | -75.49% | 117.97% | -606.42% | 757.54% | 627.78% | - | - | - |
| Operating Expenses | 4.63M | 4.01M | 40.96M | 58.53M | 68.6M | 62.52M | 61.01M | 56.63M | 53.75M | 43.27M | 22.05M | 25.03M | 13.91M | 6.78M |
| OpEx % of Revenue | - | - | 511975% | 1736.34% | 5813.47% | 3564.37% | 11194.68% | 2546.45% | 2132.94% | 1770.38% | 4965.77% | - | - | - |
| Selling, General & Admin | 3.72M | 3.49M | 6.63M | 14.56M | 16.55M | 15.39M | 13.54M | 14.73M | 15.72M | 12.93M | 8.12M | 6.08M | 3.37M | 2.38M |
| SG&A % of Revenue | - | - | 82887.5% | 431.95% | 1402.97% | 877.54% | 2483.85% | 662.23% | 623.65% | 528.93% | 1828.38% | - | - | - |
| Research & Development | 70K | 43K | 9.15M | 43.97M | 52.04M | 47.13M | 47.47M | 41.91M | 38.03M | 30.34M | 13.93M | 18.95M | 10.54M | 4.39M |
| R&D % of Revenue | - | - | 114425% | 1304.39% | 4410.51% | 2686.83% | 8710.83% | 1884.22% | 1509.29% | 1241.45% | 3137.39% | - | - | - |
| Other Operating Expenses | 838K | 476K | 25.17M | 0 | 0 | 0 | 0 | 0 | 2.79M | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -4.63M | -4.01M | -40.95M | -55.16M | -67.42M | -60.77M | -60.47M | -54.41M | -51.23M | -40.82M | -26.62M | -25.03M | -15.83M | -6.78M |
| Operating Margin % | - | - | -511875% | -1636.34% | -5713.47% | -3464.37% | -11094.68% | -2446.45% | -2032.94% | -1670.38% | -5995.05% | - | - | - |
| Operating Income Growth % | - | 90.21% | 25.76% | 18.18% | -10.95% | -0.49% | -11.13% | -6.21% | -25.49% | -53.37% | -6.36% | -58.06% | -133.71% | - |
| EBITDA | -3.74M | -3.53M | -39.66M | -53.2M | -64.9M | -58.32M | -57.83M | -51.71M | -48.81M | -38.51M | -25.93M | -24.97M | -15.8M | -6.74M |
| EBITDA Margin % | - | - | -495687.5% | -1578.26% | -5499.92% | -3325.09% | -10611.01% | -2324.95% | -1936.87% | -1575.86% | -5839.19% | - | - | - |
| EBITDA Growth % | -368.58% | 91.09% | 25.46% | 18.02% | -11.28% | -0.85% | -11.84% | -5.94% | -26.73% | -48.55% | -3.82% | -58.07% | -134.44% | - |
| D&A (Non-Cash Add-back) | 0 | 0 | 1.29M | 1.96M | 2.52M | 2.44M | 2.64M | 2.7M | 2.42M | 2.31M | 692K | 54K | 35K | 36K |
| EBIT | -3.74M | -3.53M | -23.35M | -57.27M | -66.14M | -60.56M | -59.17M | -51.35M | -48.39M | -40.32M | -25.39M | -24.98M | -15.83M | -6.44M |
| Net Interest Income | 635K | 695K | 1.43M | 2.47M | 1.26M | 208K | 1.3M | 3.04M | 2.8M | 447K | 0 | 0 | 0 | 0 |
| Interest Income | 635K | 695K | 1.43M | 2.47M | 1.27M | 210K | 1.3M | 3.06M | 2.84M | 504K | 350K | 44K | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 1K | 2K | 2K | 6K | 21K | 43K | 57K | 0 | 44K | 0 | 0 |
| Other Income/Expense | 3.98M | 3M | 17.6M | -2.11M | 1.27M | 204K | 1.29M | 3.04M | 2.79M | 447K | 10K | 44K | -1.92M | 339K |
| Pretax Income | -641K | -1M | -23.35M | -57.27M | -66.15M | -60.56M | -59.17M | -51.37M | -48.44M | -40.38M | -26.27M | -24.98M | -15.83M | -6.44M |
| Pretax Margin % | - | - | -291925% | -1698.84% | -5605.68% | -3452.74% | -10857.43% | -2309.94% | -1922.02% | -1652.09% | -5916.22% | - | - | - |
| Income Tax | 0 | 0 | 5K | 14K | 0 | 0 | 0 | 0 | 0 | 0 | 4.06M | -54K | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | -0.02% | -0.02% | 0% | 0% | 0% | 0% | 0% | 0% | -15.46% | 0.22% | 0% | 0% |
| Net Income | -641K | -1M | -23.36M | -57.28M | -66.15M | -60.56M | -59.17M | -51.37M | -48.44M | -40.38M | -26.27M | -24.98M | -15.83M | -6.44M |
| Net Margin % | - | - | -291987.5% | -1699.26% | -5605.68% | -3452.74% | -10857.43% | -2309.94% | -1922.02% | -1652.09% | -5916.22% | - | - | - |
| Net Income Growth % | -125% | 95.7% | 59.22% | 13.4% | -9.22% | -2.35% | -15.18% | -6.07% | -19.96% | -53.71% | -5.14% | -57.78% | -146.02% | - |
| Net Income (Continuing) | -641K | -1M | -23.36M | -57.28M | -66.15M | -60.56M | -59.17M | -51.37M | -48.44M | -40.38M | -20.95M | -24.98M | -15.83M | -6.44M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.05 | -0.08 | -1.92 | -8.81 | -13.57 | -15.76 | -23.67 | -24.11 | -30.42 | -90.07 | -8.83 | -34.90 | -13.98 | -5.68 |
| EPS Growth % | -145.6% | 95.83% | 78.21% | 35.08% | 13.9% | 33.42% | 1.82% | 20.74% | 66.23% | -920.05% | 74.7% | -149.64% | -146.13% | - |
| EPS (Basic) | - | -0.08 | -1.92 | -8.81 | -13.57 | -15.76 | -23.67 | -24.11 | -30.42 | -90.07 | -8.83 | -34.90 | -13.98 | -5.68 |
| Diluted Shares Outstanding | 12.4M | 12.31M | 12.2M | 6.5M | 4.78M | 3.69M | 2.39M | 2.02M | 1.59M | 448.31K | 2.98M | 715.76K | 1.13M | 1.13M |
| Basic Shares Outstanding | 12.39M | 12.31M | 12.2M | 6.5M | 4.78M | 3.69M | 2.39M | 2.02M | 1.59M | 448.31K | 2.98M | 715.76K | 1.13M | 1.13M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total cessation of operations
According to the most recent financial disclosures, Synlogic has experienced a total cessation of top-line growth, with revenue remaining at zero for several consecutive quarters following the complete abandonment of its historical project-based milestone payments and R&D reimbursement model that previously defined the company's income statement.
The transition from sporadic milestone-driven revenue to a sustained zero-revenue state indicates that the company's underlying business model has effectively collapsed. Investors should interpret this as a definitive end to the firm's operational growth phase, shifting the focus entirely toward the liquidation of remaining assets.
Based on reported figures, the company's cost structure has shifted from active clinical trial investment to a minimal overhead profile, with SG&A expenses hovering around $1 million per quarter as the firm attempts to manage its final obligations following the discontinuation of the Synpheny-3 trial.
The reduction in R&D spending suggests that management has successfully halted the primary cash-burning activities associated with clinical development. However, the persistence of SG&A costs relative to zero revenue implies that the company remains burdened by the fixed costs of maintaining a corporate shell during its strategic review.
As reported in financial statements, the company has periodically recorded positive net income figures despite generating no revenue, a phenomenon that appears to be driven by non-operating items and accounting adjustments rather than any underlying improvement in the firm's core therapeutic development or commercial capabilities.
These sporadic positive net income prints should be viewed with extreme skepticism, as they do not reflect operational viability. They likely represent the reversal of previous accruals or other non-recurring accounting events that provide no insight into the company's actual ability to generate sustainable shareholder value.
While the market may attempt to value the company based on its $14.7 million cash position, the income statement history suggests that the true net value may be lower due to the potential for undisclosed clinical trial termination liabilities and ongoing administrative costs during dissolution.
Short-term observers should monitor whether the remaining cash is sufficient to cover the full cost of winding down operations, including severance and legal fees. There is a significant risk that the company's net asset value will be eroded further before any potential distribution to shareholders can occur.
Quick answers to the most common questions about buying SYBX stock.
For fiscal year 2025, Synlogic, Inc. (SYBX) reported total revenue of $0.0M.
Synlogic, Inc. (SYBX) reported a net loss of $1.0M for the fiscal year ending 2025.